Prosecution Insights
Last updated: April 19, 2026
Application No. 17/745,183

SPHYGMOMANOMETER, BLOOD PRESSURE MEASUREMENT METHOD, AND COMPUTER-READABLE RECORDING MEDIUM

Non-Final OA §112
Filed
May 16, 2022
Examiner
HOFFPAUIR, ANDREW ELI
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Omron Healthcare Co. Ltd.
OA Round
3 (Non-Final)
39%
Grant Probability
At Risk
3-4
OA Rounds
3y 12m
To Grant
80%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allow Rate
29 granted / 75 resolved
-31.3% vs TC avg
Strong +41% interview lift
Without
With
+41.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 12m
Avg Prosecution
61 currently pending
Career history
136
Total Applications
across all art units

Statute-Specific Performance

§101
18.4%
-21.6% vs TC avg
§103
44.5%
+4.5% vs TC avg
§102
8.4%
-31.6% vs TC avg
§112
27.4%
-12.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 75 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 28th, 2025 has been entered. Claims 1-3 and 5-11 remain pending. Response to Arguments Applicant’s arguments and amendments, filed October 28th, 2025, with respect to the rejections under 35 U.S.C. 101 have been fully considered and are persuasive. The rejections under 35 U.S.C. 101 are withdrawn. Applicant’s arguments and amendments, filed October 28th, 2025, with respect to the rejections under 35 U.S.C. 103 have been fully considered and are persuasive. The rejections under 35 U.S.C. 103 are withdrawn. Claim Objections Claims 1, 6, and 9 are objected to because of the following informalities: “transit” in claim 1 lines 8 and 26 should recite “transition”. Claim 6 line 4 should recite “a certain length between one and two minutes, respectively”. “transiting” in claim 9 line 5 should recite “transitioning”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-3 and 5-11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 (claims 2-3 and 5-11 by virtue of dependency) recites “from each start time” in lines 23-24. It is unclear if each start time is referring to the predetermined time interval of the second type schedule or in addition to the predetermined time interval of the second type schedule. The limitation is suggested to recite “from the predetermined time interval”. Claim 1 (claims 2-3 and 5-11 by virtue of dependency) recites “transit to the nighttime blood pressure measurement mode when the mode instruction is input by the first switch, and initially set a time zone of the second blood pressure measurement by the second type schedule according to the designated time at which the mode instruction is input in a state where a time zone of the first blood pressure measurement by the first type schedule has been initially set”. It is unclear if the state where a time zone of the first blood pressure measurement by the first type schedule that has been initially set is set prior to the mode instruction input by the first switch or if it is set by the mode instruction input of the first switch. The limitation is suggested to recite “the programmed processor is configured to: transition to the nighttime blood pressure measurement mode when the mode instruction is input by the first switch, initially set a time zone of the first blood pressure measurement by the first type schedule according to the predetermined time, and initially set a time zone of the second blood pressure measurement by the second type schedule according to the designated time”. Claim 9 (claim 10 by virtue of dependency) recites “transiting to the nighttime blood pressure measurement mode when the mode instruction is input by the first switch, and initially setting the time zone of the second blood pressure measurement according to the designated time at which the mode instruction is input in the state where the time zone of the first blood pressure measurement has been initially set”. It is unclear if the state where the time zone of the first blood pressure measurement that has been initially set is set prior to the mode instruction input by the first switch or if it is set by the mode instruction input of the first switch. The limitation is suggested to recite “transitioning to the nighttime blood pressure measurement mode when the mode instruction is input by the first switch, initially setting the time zone of the first blood pressure measurement according to the predetermined time, and initially setting the time zone of the second blood pressure measurement according to the designated time”. Allowable Subject Matter Claims 1-3 and 5-11 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The following is a statement of reasons for the indication of allowable subject matter: The prior art of record either taken singularly or in a combination fails to anticipate or fairly suggest the limitations: “initially set a time zone of the second blood pressure measurement by the second type schedule according to the designated time at which the mode instruction is input”; “determine, prior to starting waiting for the time zones of the first blood pressure measurement and the second blood pressure measurement that have been initially set in the nighttime blood pressure measurement mode, whether or not the time zone of the first blood pressure measurement and the time zone of the second blood pressure measurement at least partially overlap with each other or whether or not a time difference between the time zone of the first blood pressure measurement and the time zone of the second blood pressure measurement is equal to or less than a predetermined value; perform an adjustment to disable one of the first blood pressure measurement and the second blood pressure measurement or to change one of a start time of the first blood pressure measurement and a start time of the second blood pressure measurement to provide an idle time between the first blood pressure measurement and the second blood pressure measurement in a case a result of the determination is an affirmative result that the time zones partially overlap or the time difference is equal to or less than the predetermined value”. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Nakazawa (JP2003061919A English Translation) directed to an electronic sphygmomanometer having a button 503 operated to specify nighttime blood pressure measurement and provisionally set the time for nighttime measurement (para. [0086, 0112], fig. 9) ; Tao (CN 101779952 A English Translation) directed to a method, device, and monitor for controlling blood pressure measurement intervals; Lin (US 20100280395 A1) directed to a system and a method for hypertension management having a device programmed such as to operate in accordance with a predetermined measurement schedule in addition to a prestored, guideline based schedule (para. [0058-0060]). Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW ELI HOFFPAUIR whose telephone number is (571)272-4522. The examiner can normally be reached Monday-Friday 8:00-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Charles Marmor II can be reached at (571) 272-4730. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.E.H./Examiner, Art Unit 3791 /AURELIE H TU/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

May 16, 2022
Application Filed
May 16, 2022
Response after Non-Final Action
Jan 28, 2025
Non-Final Rejection — §112
May 08, 2025
Response Filed
Jul 24, 2025
Final Rejection — §112
Oct 28, 2025
Request for Continued Examination
Nov 03, 2025
Response after Non-Final Action
Jan 16, 2026
Non-Final Rejection — §112
Mar 04, 2026
Examiner Interview Summary
Mar 04, 2026
Applicant Interview (Telephonic)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12593987
FOREHEAD TEMPERATURE MEASUREMENT SYSTEM WITH HIGH ACCURACY
2y 5m to grant Granted Apr 07, 2026
Patent 12564423
SYSTEMS AND METHODS FOR ACCESSING A RENAL CAPSULE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
2y 5m to grant Granted Mar 03, 2026
Patent 12533043
DEVICE FOR PROCESSING AND VISUALIZING DATA OF AN ELECTRIC IMPEDANCE TOMOGRAPHY APPARATUS FOR DETERMINING AND VISUALIZING REGIONAL VENTILATION DELAYS IN THE LUNGS
2y 5m to grant Granted Jan 27, 2026
Patent 12521023
TEMPERATURE SELF-COMPENSATION INTERVENTIONAL OPTICAL FIBER PRESSURE GUIDEWIRE AND WIRELESS FFR MONITOR
2y 5m to grant Granted Jan 13, 2026
Patent 12502514
Vascular Access Device Adapter
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
39%
Grant Probability
80%
With Interview (+41.1%)
3y 12m
Median Time to Grant
High
PTA Risk
Based on 75 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month